A single-arm, decentralised, real-world evidence pilot study to assess the impact of Symprove in people with Ehlers- Danlos Syndrome (EDS)
Ehlers-Danlos syndromes
All participants will receive a 12-week course of Symprove (70 ml per day), a water-based solution that contains billions of live and active bacteria. The water-based formula makes sure that the bacteria are alive, active and ready to help stimulate the good bacteria already in the gut. After completing a screening questionnaire, an online consent form and a baseline survey, participants will be able to order Symprove using a unique code. Participants will also complete study surveys at weeks 6 and 12. The study does not involve any study visits.
1. Adults (18-75 years) resident in the UK who have either self-diagnosed or received a medical diagnosis of EDS (any subtype)
1. Currently taking probiotics or prebiotics supplements (e.g. Bimuno) or yogurts containing probiotics (e.g. Yakult, Actimel) 2. Taken Symprove in the last 3 months 3. Taken antibiotics in the last 4 weeks 4. Diagnosed with gut conditions other than DGBIs, such as inflammatory bowel disease (e.g. Crohn’s disease or ulcerative colitis), coeliac disease, hepatitis, gallstones 5. Received gastrointestinal surgery, cancer treatment or been hospitalised in the last 6 months 6. Experiencing any psychological issues (such as depression, bipolar illness, psychosis) that are unstable and/or have recently changed medications for psychological issues 7. Diagnosed with any significant heart, lung or kidney issues 8. Currently pregnant or breastfeeding 9. Patients taking part in other interventional research where they are receiving treatment